- Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q3 Non-GAAP EPS of $1.08 misses by $0.04 .
- Revenue of $387.9M (+31.0% Y/Y) beats by $11.15M .
-
INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $376 Million
-
INGREZZA ® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1.425 Billion
-
Supplemental New Drug Application (sNDA) of Valbenazine For the Treatment of Chorea in Patients with Huntington Disease Submitted to the U.S. Food and Drug Administration
For further details see:
Neurocrine Biosciences Non-GAAP EPS of $1.08 misses by $0.04, revenue of $387.9M beats by $11.15M